What is the fair value of Genelux Corp (NASDAQ-GNLX) stock?

The current fair value estimate for Genelux Corp (NASDAQ-GNLX) is $2.59. This implies an estimated upside of 2.3% versus the current market price.

Is Genelux Corp (NASDAQ-GNLX) undervalued or overvalued?

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 2.3% versus the current market price.

What is the analyst price target for NASDAQ-GNLX stock?

The available analyst price target for Genelux Corp (NASDAQ-GNLX) is $18.83. The analyst target implies estimated upside of 644.4%.

How is the financial health of Genelux Corp?

The current financial health read for Genelux Corp (NASDAQ-GNLX) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Genelux Corp's next earnings date?

The next earnings date currently listed for Genelux Corp (NASDAQ-GNLX) is November 18, 2026.

Does Genelux Corp (NASDAQ-GNLX) pay dividends?

The latest available data indicates no current dividend yield for Genelux Corp (NASDAQ-GNLX).

What is the market capitalization of Genelux Corp?

The current market capitalization listed for Genelux Corp is 113.4 M.

What is the enterprise value of Genelux Corp?

The current enterprise value listed for Genelux Corp is 97.124 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Genelux Corp?

The ticker symbol for Genelux Corp is NASDAQ-GNLX, and the stock is listed on NASDAQ.

Where is Genelux Corp (NASDAQ-GNLX) listed?

Genelux Corp (NASDAQ-GNLX) is listed on NASDAQ.

What is the debt-to-total-capital ratio for Genelux Corp?

The current debt-to-total-capital ratio listed for Genelux Corp is 2.1%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Genelux Corp?

The free float listed for Genelux Corp is 81.3%. Free float helps investors understand how much of the share base is available for public trading.

Genelux Corp (GNLX) Fair Value & Stock Analysis

Genelux Corp (GNLX)

Genelux Corp is a clinical-stage biopharmaceutical company listed on the NASDAQ under the ticker GNLX. The company is developing oncolytic virus-based immunotherapies for hard-to-treat solid tumors, with a focus on cancers such as ovarian cancer. Its lead candidate is Olvi-Vec, a modified vaccinia virus program being advanced for ovarian cancer treatment. Genelux also maintains CHOICE, a technology and development platform, and has built a library of isolated and engineered oncolytic VACV-based product candidates. In addition, the company has a licensing agreement with Newsoara BioPharma Co. Ltd. covering research, development, commercialization, and related use of Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau. Genelux was incorporated in 2001 and is based in Westlake Village, California.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Dividend Yield	Next Earnings Date	Price-to-Book Ratio	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Free Cash Flow / Net Income
NASDAQ-GNLX	$2.59	2.3% Upside	Fair	$18.83	644.4% Upside	Bargain	Weak	0.0%	November 18, 2026	7.0x	14,171.8x	113.4 M	97.124 M	2.1%	81.3%	-13.5	80.6%